Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis

Multiple Sclerosis

Volumn 1, Issue 1, 1995, Pages 2-9

  Liu, X ^a   Yao, D L ^a   Webster, Hde F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

blood brain barrier; demyelination; experimental autoimmune encephalomyelitis; insulin like growth factor I; multiple sclerosis; myelin regeneration; oligodendroglia

Indexed keywords

SOMATOMEDIN C;

ACUTE DISEASE; ALLERGIC ENCEPHALOMYELITIS; ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; DISEASE MODEL; DRUG EFFECT; GAIT; HOSPITALIZATION; LEWIS RAT; LIMB; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; RAT; SPINAL CORD; TIME;

ACUTE DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; BODY WEIGHT; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EXTREMITIES; GAIT; INSULIN-LIKE GROWTH FACTOR I; MALE; PSYCHOMOTOR PERFORMANCE; RATS; RATS, INBRED LEW; SEVERITY OF ILLNESS INDEX; SPINAL CORD; TIME FACTORS;

EID: 0029279164     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/135245859500100102     Document Type: Article

References (48)

1. Clemmons DR. (1991) Insulin-like growth factor binding proteins. Trends Endocrinol Metab 1: 412–417.
2. Rutanen E-M, Pekonen F. (1990) Insulin-like growth factors and their binding proteins. Acta Endocrinol 123: 7–13.
3. Bondy CA. (1991) Transient IGF-I gene expression during the maturation offunctionally related central projection neurons. J Neurosci 11: 3442–3455.
4. Bondy CA, et al. (1992) Cellular pattern of type-I insulin-like growth factor receptor gene expression during maturation of the rat brain: comparison with insulin-like growth factors I and II. Neuroscience 46: 909–923.
5. Lee W.-H., Javedan S, Bondy CA. (1992) Coordinate expression of insulin-like growth factor system compo nents by neurons and neuroglia during retinal and cerebellar development. J Neurosci 12: 4737–4744.
6. Rechler MM, Nissley SP. (1990) Insulin-like growth factors. Handb Exp Pharmacol 95: 263–367.
7. Barres BA, et al. (1993) Multiple extracellular signals are required for long-term oligodendrocyte survival. Development 118: 283–295.
8. McMorris FA, Dubois-Dalcq M. (1988) Insulin-like growth factor I promotes cell proliferation and oligodendroglial commitment in rat progenitor cells developing in vitro. J Neurosci Res 21: 199–209.
9. McMorris FA, et al. (1986) Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci USA 83: 822–826.
10. Mozell RL, McMorris FA. (1991) Insulin-like growth factor I stimulates oligodendrocyte development and myelination in rat brain aggregate cultures. J Neurosci Res 30: 382–390.
11. Carson MJ, et al. (1993) Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 10: 729–740.
12. Mathews LS, et al. (1988) Growth enhancement of transgenic mice expressing human insulin-like growth factor I*. Endocrinology 123: 2827–2833.
13. Beck KD, et al. (1995) Mice homozygous for disrupted insulin-like growth factor I gene display reduced myelination in the CNS and reduced numbers of hippocampal granule and striatal parvalbumin-containing neurons. Neuron (in press).
14. Komoly S, et al. (1992) Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination. Proc Natl Acad Sci USA 89: 1894–1898.
15. Liu X, et al. (1994) Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein, IGFBP-2, during demyelination induced by experimental autoimmune encephalomyelitis. Mol Cell Neurosci 5: 418–430.
16. Yao D.-L., et al. (1995) Cryogenic spinal cord injury induces astrocytic gene expression of insulin-like growth factor-I (IGF-I) and IGF binding protein 2 (IGFBP-2) during myelin regeneration. J Neurosci Res, 40: 647–659.
17. Raine CS. (1984) Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab Invest 50: 608–635.
18. Raine CS. (1991) Multiple sclerosis: a pivotal role for the T cell in lesion development. Neuropathol Appl Neurobiol 17: 265–274.
19. Somogyi P, Takagi H. (1982) A note on the use of picric acid-paraformaldehyde-glutaraldehyde fixative for correlated light and electron microscopic immunocyto-chemistry. Neuroscience 7: 1779–1783.
20. Bondy C. (1994) Clinical uses of insulin-like growth factor-I. Ann Int Med 120: 593–601.
21. Kitz K, et al. (1984) Blood—brain barrier in chronic relapsing experimental allergic encephalomyelitis: a correlative study between cerebrospinal fluid protein concentrations and tracer leakage in the central nervous system. Acta Neuropathol 63: 41–50.
22. Oldstone MBA, Dixon FJ. (1968) Immunohistochemical study of allergic encephalomyelitis. Am J Pathol 52: 251–263.
23. Paterson PY, Koh CS, Kwaan HC. (1987) Role of the clotting system in the pathogenesis of neuroimmunologic disease. Fed Proc 46: 91–96.
24. Butter C, et al. (1991) Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomye litis in Biozzi AB/H mice. J Neurolog Sci 104: 9–12.
25. Bar RS, et al. (1988) Insulin, insulin-like growth factors and vascular endothelium. Am J Med 85(Suppil. 5A): 59–70.
26. Bar RS, et al. (1989) Insulin-like growth factor binding proteins from vascular endothelial cells: purification, characterization, and intrinsic biological activities. Endocrinology 125: 1910–1920.
27. Pardridge WM. (1993) Transport of insulin-related peptides and glucose across the blood-brain barrier. Ann N Y Acad Sci 692: 126–137.
28. Rosenfeld RG, et al. (1987) Demonstration and structural comparison of receptors for insulin-like growth factor-I and-II (IGF-I and-II) in brain and blood-brain barrier. Biochem Biophys Res Commun 149: 159–166.
29. Grant MB, et al. (1993) Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: Comparative studies with basic fibroblast growth factor. Diabetologia 36: 282–291.
30. Lassmann H, Rossler K, Zimprich F, Vass K. (1991) Expression of adhesion molecules and histocompatibility antigens at the blood-brain barrier. Brain Pathol 1: 115–123.
31. Raine CS, Cannella B. (1992) Adhesion molecules and central nervous system inflammation. Sem Neurosci 4: 207–211.
32. Raine CS, et al. (1990) Homing to central nervous system vasculature by antigen-specific lymphocytes. II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab Invest 634: 476–489.
33. Archelos JJ, et al. (1993) Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neural 34: 145–154.
34. Willenborg DO, et al. (1993) ICAM-1-dependent pathway is not critically involved in the inflammatory process of autoimmune encephalomyelitis or in cytokine-induced inflammation of the central nervous system. J Neuroimmunol 45: 147–154.
35. Cannella B, Cross AH, Raine CS. (1993) Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis. J Neuroimmunol 46: 43–56.
36. Lindsey JW, Steinman L. (1993). Competitive PCR quantification of CD4, CDS, ICAM-1, VCAM-1, and MHC class II mRNA in the central nervous system during development and resolution of experimental allergic encephalomyelitis. J Neuroimmunol 48: 227–234.
37. Clark R, et al. (1993) Insulin-like growth factor-1 stimulation of lymphopoiesis. J Clin Invest 92: 540–548.
38. Robbins K, et al. (1994) Immunological effects of insulin-like growth factor-I-enhancement of immunoglobulin synthesis. Clin Exp Immunol 95: 337–342.
39. Tapson VF, et al. (1988) Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro. J Clin Invest 82: 950–957.
40. Martin R, McFarland HF, McFarlin DE. (1992) Immunological aspects of demyelinating diseases. Anna Rev Immunol 10: 153–187.
41. Racke MK, et al. (1993) Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β2. J Neuroimmunol 46: 175–184.
42. Selmaj K, Raine CS, Cross AH. (1991) Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neural 30: 694–700.
43. Vandenbark AA, Hashim G, offner H. (1993) TCR peptide therapy in autoimmune diseases. Intern Rev Immunol 9: 251–276.
44. Brück W, et al. (1994) Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 35: 65–73.
45. McDonald WI. (1994) The pathological and clinical dynamics of multiple sclerosis. J Neuropathol Exp Neurol 53: 338–343.
46. Ozawa K, et al. (1995) Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117: 1311–1322.
47. Raine CS. (1994) The Dale E. McFarlin Memorial Lecture: The immunology of the multiple sclerosis lesion. Ann Neurol 36 suppl.: S61–S72.
48. Grinspan JB, et al. (1994) Protein growth factors as potential therapies for central nervous system demyeli-native disorders. Ann Neurol 36 suppl.: S140–S142.